Bicycle Therapeutics plc
BCYC
$7.12
$0.020.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -70.73% | 169.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -70.73% | 169.07% | |||
| Cost of Revenue | 24.02% | 194.16% | |||
| Gross Profit | -44.01% | -169.31% | |||
| SG&A Expenses | -19.28% | 49.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.65% | 12.34% | |||
| Operating Income | -23.36% | -3.76% | |||
| Income Before Tax | -28.04% | -16.82% | |||
| Income Tax Expenses | 78.75% | -0.46% | |||
| Earnings from Continuing Operations | -29.95% | -17.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.95% | -17.16% | |||
| EBIT | -23.36% | -3.76% | |||
| EBITDA | -23.82% | -3.96% | |||
| EPS Basic | -29.85% | -16.93% | |||
| Normalized Basic EPS | -27.93% | -7.51% | |||
| EPS Diluted | -29.85% | -16.93% | |||
| Normalized Diluted EPS | -27.93% | -7.51% | |||
| Average Basic Shares Outstanding | 0.08% | 0.21% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||